Found: 74
Select item for more details and to access through your institution.
Development of sofosbuvir for the treatment of hepatitis C virus infection.
- Published in:
- Annals of the New York Academy of Sciences, 2015, v. 1358, n. 1, p. 56, doi. 10.1111/nyas.12832
- By:
- Publication type:
- Article
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 6, p. 770, doi. 10.1111/jvh.13067
- By:
- Publication type:
- Article
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 3, p. 337, doi. 10.1111/jvh.13038
- By:
- Publication type:
- Article
Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction.
- Published in:
- 2017
- By:
- Publication type:
- Case Study
Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection.
- Published in:
- Digestive Diseases & Sciences, 2015, v. 60, n. 5, p. 1457, doi. 10.1007/s10620-014-3486-7
- By:
- Publication type:
- Article
Viral Suppression and Cirrhosis Regression with Tenofovir Disoproxil Fumarate in Asians with Chronic Hepatitis B.
- Published in:
- Digestive Diseases & Sciences, 2015, v. 60, n. 1, p. 260, doi. 10.1007/s10620-014-3336-7
- By:
- Publication type:
- Article
Liver transplantation in Jehovah's Witness patients in Australasia.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Nadolol reduces insulin sensitivity in liver cirrhosis: a randomized double-blind crossover trial.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Polymorphism in intron 1 of the interferon-gamma gene influences both serum immunoglobulin E levels and the risk for chronic hepatitis B virus infection in Polynesians.
- Published in:
- Immunogenetics, 2007, v. 59, n. 3, p. 187, doi. 10.1007/s00251-006-0184-4
- By:
- Publication type:
- Article
Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment.
- Published in:
- European Journal of Clinical Pharmacology, 2019, v. 75, n. 2, p. 217, doi. 10.1007/s00228-018-2576-4
- By:
- Publication type:
- Article
Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Management of Hep C -- A Cocktail of Antivirals.
- Published in:
- Medical Journal of Malaysia, 2011, v. 66, p. 39
- By:
- Publication type:
- Article
FK 506 rescue therapy for intractable liver allograft rejection.
- Published in:
- Transplant International, 1994, v. 7, n. S1, p. 70, doi. 10.1111/j.1432-2277.1994.tb01313.x
- By:
- Publication type:
- Article
Genetic Diversity and Linkage Disequilibrium in the Polynesian Population of Niue Island.
- Published in:
- Human Biology, 2006, v. 78, n. 2, p. 131, doi. 10.1353/hub.2006.0031
- By:
- Publication type:
- Article
Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-46609-7
- By:
- Publication type:
- Article
Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
- Published in:
- PLoS ONE, 2021, v. 16, n. 5, p. 1, doi. 10.1371/journal.pone.0251552
- By:
- Publication type:
- Article
Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non‐alcoholic steatohepatitis or alcoholic liver disease: a 20‐year experience from a national programme.
- Published in:
- Internal Medicine Journal, 2019, v. 49, n. 11, p. 1405, doi. 10.1111/imj.14304
- By:
- Publication type:
- Article
Safety, pharmacokinetics and antiviral activity of ABI‐H2158, a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study.
- Published in:
- Journal of Viral Hepatitis, 2023, v. 30, n. 3, p. 209, doi. 10.1111/jvh.13764
- By:
- Publication type:
- Article
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
- Published in:
- Journal of Viral Hepatitis, 2021, v. 28, n. 11, p. 1635, doi. 10.1111/jvh.13600
- By:
- Publication type:
- Article
Asian consensus recommendations on optimizing the diagnosis and initiation of treatment of hepatitis B virus infection in resource‐limited settings.
- Published in:
- Journal of Viral Hepatitis, 2020, v. 27, n. 5, p. 466, doi. 10.1111/jvh.13244
- By:
- Publication type:
- Article
Surveillance factors change outcomes in patients with hepatocellular carcinoma due to chronic hepatitis C virus infection in New Zealand.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 12, p. 1372, doi. 10.1111/jvh.13179
- By:
- Publication type:
- Article
Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 9, p. 1127, doi. 10.1111/jvh.13132
- By:
- Publication type:
- Article
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study.
- Published in:
- Annals of Internal Medicine, 2022, v. 175, n. 9, p. 1221, doi. 10.7326/M21-4119
- By:
- Publication type:
- Article
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy.
- Published in:
- Clinical Infectious Diseases, 2020, v. 71, n. 7, p. e115, doi. 10.1093/cid/ciz1089
- By:
- Publication type:
- Article
Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs.
- Published in:
- Clinical Infectious Diseases, 2020, v. 70, n. 9, p. 1900, doi. 10.1093/cid/ciz546
- By:
- Publication type:
- Article
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease.
- Published in:
- Clinical Infectious Diseases, 2019, v. 69, n. 10, p. 1657, doi. 10.1093/cid/ciz022
- By:
- Publication type:
- Article
A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults.
- Published in:
- Antiviral Therapy, 2023, v. 28, n. 3, p. 1, doi. 10.1177/13596535231172878
- By:
- Publication type:
- Article
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants.
- Published in:
- Antiviral Therapy, 2023, v. 28, n. 1, p. 1, doi. 10.1177/13596535231151626
- By:
- Publication type:
- Article
Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand.
- Published in:
- New Zealand Medical Journal, 2014, v. 127, n. 1407, p. 61
- By:
- Publication type:
- Article
The impact of oral antiviral therapy on long-term survival of hepatitis B surface antigen-positive patients on haemodialysis.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
The impact of oral antiviral therapy on long-term survival of hepatitis B surface antigen-positive patients on haemodialysis.
- Published in:
- New Zealand Medical Journal, 2014, v. 127, n. 1396, p. 34
- By:
- Publication type:
- Article
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.
- Published in:
- Open Forum Infectious Diseases, 2017, v. 4, n. 3, p. 1, doi. 10.1093/ofid/ofx154
- By:
- Publication type:
- Article
PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2024, v. 13, n. 3, p. 256, doi. 10.1159/000533650
- By:
- Publication type:
- Article
Plasma and breast milk pharmacokinetics of tenofovir alafenamide of mothers with chronic hepatitis B infection—Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 3, p. 548, doi. 10.1111/apt.17102
- By:
- Publication type:
- Article
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 3, p. 510, doi. 10.1111/apt.17040
- By:
- Publication type:
- Article
Peginterferon α-2a (40kD) [Pegasys[sup ®]] Improves HR-QOL Outcomes Compared with Unmodified Interferon α-2a [Roferon[sup ®]-A]: In Patients with Chronic Hepatitis C.
- Published in:
- PharmacoEconomics, 2003, v. 21, n. 5, p. 341, doi. 10.2165/00019053-200321050-00005
- By:
- Publication type:
- Article
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Graft-vs-Host Disease After Liver Transplantation: A Diagnostic and Management Challenge.
- Published in:
- ACG Case Reports Journal, 2020, v. 7, n. 12, p. 1, doi. 10.14309/crj.0000000000000499
- By:
- Publication type:
- Article
RISK BEHAVIOUR TRAJECTORIES AMONG PEOPLE TREATED FOR RECENT HCV INFECTION.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 238
- By:
- Publication type:
- Article
TARGET3D: GLECAPREVIR-PIBRENTASVIR FOR FOUR WEEKS IN PEOPLE WITH RECENT HCV INFECTION.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 80
- By:
- Publication type:
- Article
Clinical recurrence of hepatitis A following liver transplantation for acute liver failure.
- Published in:
- Journal of Medical Virology, 1995, v. 45, n. 1, p. 35, doi. 10.1002/jmv.1890450107
- By:
- Publication type:
- Article
Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients.
- Published in:
- Clinical & Molecular Hepatology, 2024, v. 30, n. 2, p. 191, doi. 10.3350/cmh.2023.0422
- By:
- Publication type:
- Article
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Reactivation of Hepatitis B Virus Following Treatment of Hepatitis C Virus Infection in Coinfected Patients.
- Published in:
- 2017
- By:
- Publication type:
- Letter to the Editor
No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
- Published in:
- Clinical Infectious Diseases, 2016, v. 63, n. 9, p. 1202, doi. 10.1093/cid/ciw507
- By:
- Publication type:
- Article
Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials.
- Published in:
- Clinical Infectious Diseases, 2014, v. 59, n. 12, p. 1666, doi. 10.1093/cid/ciu697
- By:
- Publication type:
- Article
Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long‐term follow‐up study.
- Published in:
- Liver International, 2022, v. 42, n. 6, p. 1278, doi. 10.1111/liv.15211
- By:
- Publication type:
- Article
Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies.
- Published in:
- Liver International, 2020, v. 40, n. 10, p. 2385, doi. 10.1111/liv.14535
- By:
- Publication type:
- Article